169 related articles for article (PubMed ID: 38033123)
21. Hallucinogenic 5-HT2AR agonists LSD and DOI enhance dopamine D2R protomer recognition and signaling of D2-5-HT2A heteroreceptor complexes.
Borroto-Escuela DO; Romero-Fernandez W; Narvaez M; Oflijan J; Agnati LF; Fuxe K
Biochem Biophys Res Commun; 2014 Jan; 443(1):278-84. PubMed ID: 24309097
[TBL] [Abstract][Full Text] [Related]
22. Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action.
Dos Santos RG; Hallak JE; Baker G; Dursun S
J Psychopharmacol; 2021 Apr; 35(4):453-458. PubMed ID: 33740877
[TBL] [Abstract][Full Text] [Related]
23. Structural pharmacology and therapeutic potential of 5-methoxytryptamines.
Warren AL; Lankri D; Cunningham MJ; Serrano IC; Parise LF; Kruegel AC; Duggan P; Zilberg G; Capper MJ; Havel V; Russo SJ; Sames D; Wacker D
Nature; 2024 Jun; 630(8015):237-246. PubMed ID: 38720072
[TBL] [Abstract][Full Text] [Related]
24. In vitro structure-activity relationship determination of 30 psychedelic new psychoactive substances by means of β-arrestin 2 recruitment to the serotonin 2A receptor.
Pottie E; Cannaert A; Stove CP
Arch Toxicol; 2020 Oct; 94(10):3449-3460. PubMed ID: 32627074
[TBL] [Abstract][Full Text] [Related]
25. Hallucinogens and Serotonin 5-HT
López-Giménez JF; González-Maeso J
Curr Top Behav Neurosci; 2018; 36():45-73. PubMed ID: 28677096
[TBL] [Abstract][Full Text] [Related]
26. In vitro assays for the functional characterization of (psychedelic) substances at the serotonin receptor 5-HT
Pottie E; Stove CP
J Neurochem; 2022 Jul; 162(1):39-59. PubMed ID: 34978711
[TBL] [Abstract][Full Text] [Related]
27. Pharmacological Mechanism of the Non-hallucinogenic 5-HT
Cunningham MJ; Bock HA; Serrano IC; Bechand B; Vidyadhara DJ; Bonniwell EM; Lankri D; Duggan P; Nazarova AL; Cao AB; Calkins MM; Khirsariya P; Hwu C; Katritch V; Chandra SS; McCorvy JD; Sames D
ACS Chem Neurosci; 2023 Jan; 14(1):119-135. PubMed ID: 36521179
[TBL] [Abstract][Full Text] [Related]
28. Differences across sexes on head-twitch behavior and 5-HT
Jaster AM; Younkin J; Cuddy T; de la Fuente Revenga M; Poklis JL; Dozmorov MG; González-Maeso J
Neurosci Lett; 2022 Sep; 788():136836. PubMed ID: 35963476
[TBL] [Abstract][Full Text] [Related]
29. A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT
Raval NR; Johansen A; Donovan LL; Ros NF; Ozenne B; Hansen HD; Knudsen GM
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467676
[TBL] [Abstract][Full Text] [Related]
30. Psychedelic-inspired drug discovery using an engineered biosensor.
Dong C; Ly C; Dunlap LE; Vargas MV; Sun J; Hwang IW; Azinfar A; Oh WC; Wetsel WC; Olson DE; Tian L
Cell; 2021 May; 184(10):2779-2792.e18. PubMed ID: 33915107
[TBL] [Abstract][Full Text] [Related]
31. Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex.
González-Maeso J; Yuen T; Ebersole BJ; Wurmbach E; Lira A; Zhou M; Weisstaub N; Hen R; Gingrich JA; Sealfon SC
J Neurosci; 2003 Oct; 23(26):8836-43. PubMed ID: 14523084
[TBL] [Abstract][Full Text] [Related]
32. Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans.
Stenbæk DS; Madsen MK; Ozenne B; Kristiansen S; Burmester D; Erritzoe D; Knudsen GM; Fisher PM
J Psychopharmacol; 2021 Apr; 35(4):459-468. PubMed ID: 33501857
[TBL] [Abstract][Full Text] [Related]
33. Investigation of the 2,5-Dimethoxy Motif in Phenethylamine Serotonin 2A Receptor Agonists.
Marcher-Rørsted E; Halberstadt AL; Klein AK; Chatha M; Jademyr S; Jensen AA; Kristensen JL
ACS Chem Neurosci; 2020 May; 11(9):1238-1244. PubMed ID: 32212672
[TBL] [Abstract][Full Text] [Related]
34. Discovery and Structure-Activity Relationships of 2,5-Dimethoxyphenylpiperidines as Selective Serotonin 5-HT
M Ro Rsted E; Jensen AA; Smits G; Frydenvang K; Kristensen JL
J Med Chem; 2024 May; 67(9):7224-7244. PubMed ID: 38648420
[TBL] [Abstract][Full Text] [Related]
35. Pharmacologic Activity of Substituted Tryptamines at 5-Hydroxytryptamine (5-HT)
Kozell LB; Eshleman AJ; Swanson TL; Bloom SH; Wolfrum KM; Schmachtenberg JL; Olson RJ; Janowsky A; Abbas AI
J Pharmacol Exp Ther; 2023 Apr; 385(1):62-75. PubMed ID: 36669875
[TBL] [Abstract][Full Text] [Related]
36. G
Liu X; Zhu H; Gao H; Tian X; Tan B; Su R
Biochem Biophys Res Commun; 2022 Apr; 598():20-25. PubMed ID: 35149433
[TBL] [Abstract][Full Text] [Related]
37. [Up-to-Date on clinical and preclinical studies of psilocybin therapy].
Ibi D
Nihon Yakurigaku Zasshi; 2024; 159(4):214-218. PubMed ID: 38945903
[TBL] [Abstract][Full Text] [Related]
38. Bespoke library docking for 5-HT
Kaplan AL; Confair DN; Kim K; Barros-Álvarez X; Rodriguiz RM; Yang Y; Kweon OS; Che T; McCorvy JD; Kamber DN; Phelan JP; Martins LC; Pogorelov VM; DiBerto JF; Slocum ST; Huang XP; Kumar JM; Robertson MJ; Panova O; Seven AB; Wetsel AQ; Wetsel WC; Irwin JJ; Skiniotis G; Shoichet BK; Roth BL; Ellman JA
Nature; 2022 Oct; 610(7932):582-591. PubMed ID: 36171289
[TBL] [Abstract][Full Text] [Related]
39. Animal Behavior in Psychedelic Research.
Odland AU; Kristensen JL; Andreasen JT
Pharmacol Rev; 2022 Oct; 74(4):1176-1205. PubMed ID: 36180111
[TBL] [Abstract][Full Text] [Related]
40. The possible place for psychedelics in pharmacotherapy of mental disorders.
Wojtas A
Pharmacol Rep; 2023 Dec; 75(6):1313-1325. PubMed ID: 37934320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
